Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ACP3 | P15309 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054365 | 0.87 | ALDH1A1 (0.52) | ALDH1A1CYP2D6CYP2C9CYP2C19RECQL | |
| SCHEMBL3727438 | 0.85 | LMNA (0.55) | PTGS1PTGS2ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL2353731 | 0.85 | ALDH1A1 (0.53) | ALDH1A1CYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL11092415 | 0.84 | MAPT (0.48) | ALDH1A1AKR1C3AKR1C2LMNAMEN1 | |
| SCHEMBL27474822 | 0.84 | L3MBTL1 (0.55) | ALDH1A1AKR1C3AKR1C2LMNAMEN1 | |
| SCHEMBL15229336 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL27780284 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL5042702 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL27515178 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL10093132 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNAMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106336382-B | 4-saturated cyclic substituted aniline protein kinase inhibitor | 杭州雷索药业有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | GLAXO GROUP LIMITED | 2010-08-12 | — | — | US | disclosed |
| US-7732600-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| EP-2145622-A1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | Glaxo Group Limited (GB) | 2010-01-20 | — | — | EP | disclosed |
| US-20090312546-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2009-12-17 | — | — | US | disclosed |
| EP-1876174-B1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LTD (GB) | 2009-11-11 | — | — | EP | disclosed |
| US-7592346-B2 | e.g. 3-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-1,3-oxazolidin-2-one; serotonin receptor antagonist and inverse agonists, agonists or partial agonists, serotonin reuptake inhibitor; antidepressant, anxiolytic agent | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| CN-100441571-C | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LTD (GB) | 2008-12-10 | — | — | CN | disclosed |
| US-7459456-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2008-12-02 | — | — | US | disclosed |
| US-7279481-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2007-07-19 | — | — | US | disclosed |
| CN-1852896-A | Quinoline and quinazoline derivatives having affinity for 5HT 1-type receptors | GLAXO GROUP LTD (GB) | 2006-10-25 | — | — | CN | disclosed |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| EP-1646613-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-04-19 | — | — | EP | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| WO-2005014552-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| EP-0077662-B1 | PREPARATION OF NITROARYLACETIC ACID ESTERS AND DERIVATIVES THEREOF | ETHYL CORPORATION (US) | 1985-10-02 | — | — | EP | disclosed |
| US-4476315-A | NITROARYLACETIC ACID ESTERS FROM NITROAROMATIC COMPOUNDS | ETHYL CORPORATION (US) | 1984-10-09 | — | — | US | disclosed |
| EP-0077662-A1 | Preparation of nitroarylacetic acid esters and derivatives thereof | ETHYL CORPORATION (US) | 1983-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | PTGS1 2693/4885PTGS2 3358/4885ALDH1A1 1256/4885 |
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | OPRK1, OPRL1, OPRD1 | PTGS1 659/4885PTGS2 1508/4885ALDH1A1 2366/4885 |
| US-20090312546-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | PTGS1 840/4885PTGS2 1878/4885ALDH1A1 3105/4885 |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | PTGS1 1192/4885PTGS2 2415/4885ALDH1A1 1826/4885 |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | HTR1A, HTR1D, HTR1F | PTGS1 1192/4885PTGS2 2415/4885ALDH1A1 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.